Adenocarcinoma from the patient with 9 months disease stabilization harbored 21 mutations, including p53, ERBB2 and ERCC1 mutations as well as focal amplifications involving ERBB2 and CCND1. This evidence concerns the gene ERBB2 and adenocarcinoma.